IE922421A1 - Test for the rapid evaluation of ischemic states and kit - Google Patents
Test for the rapid evaluation of ischemic states and kitInfo
- Publication number
- IE922421A1 IE922421A1 IE242192A IE922421A IE922421A1 IE 922421 A1 IE922421 A1 IE 922421A1 IE 242192 A IE242192 A IE 242192A IE 922421 A IE922421 A IE 922421A IE 922421 A1 IE922421 A1 IE 922421A1
- Authority
- IE
- Ireland
- Prior art keywords
- sample
- metal ions
- alkyl
- metal
- kit
- Prior art date
Links
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 38
- 238000012360 testing method Methods 0.000 title claims abstract description 12
- 238000011156 evaluation Methods 0.000 title description 2
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 64
- 210000002966 serum Anatomy 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000012530 fluid Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 34
- 229910052751 metal Inorganic materials 0.000 claims description 23
- 239000002184 metal Substances 0.000 claims description 23
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 23
- 238000001514 detection method Methods 0.000 claims description 19
- 150000003573 thiols Chemical class 0.000 claims description 17
- 210000002381 plasma Anatomy 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- -1 alkyl thioalcohol Chemical compound 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 11
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 229910017052 cobalt Inorganic materials 0.000 claims description 6
- 239000010941 cobalt Substances 0.000 claims description 6
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000001479 atomic absorption spectroscopy Methods 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 229910052787 antimony Inorganic materials 0.000 claims description 2
- 229910052785 arsenic Inorganic materials 0.000 claims description 2
- 238000001636 atomic emission spectroscopy Methods 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- 229910052793 cadmium Inorganic materials 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 229910052745 lead Inorganic materials 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 229910001428 transition metal ion Inorganic materials 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 53
- 102000004169 proteins and genes Human genes 0.000 description 53
- 108090000623 proteins and genes Proteins 0.000 description 53
- 239000000523 sample Substances 0.000 description 51
- 239000000047 product Substances 0.000 description 19
- 206010008479 Chest Pain Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010093894 Xanthine oxidase Proteins 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000001269 cardiogenic effect Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010002388 Angina unstable Diseases 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 108010032088 Calpain Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 2
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical compound NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 1
- HHFDWBHFYINSFR-UHFFFAOYSA-N 2-sulfanylpropanedioic acid Chemical compound OC(=O)C(S)C(O)=O HHFDWBHFYINSFR-UHFFFAOYSA-N 0.000 description 1
- IYGAMTQMILRCCI-UHFFFAOYSA-N 3-aminopropane-1-thiol Chemical compound NCCCS IYGAMTQMILRCCI-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010050702 Crush syndrome Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- JDMUPRLRUUMCTL-VIFPVBQESA-N D-pantetheine 4'-phosphate Chemical compound OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS JDMUPRLRUUMCTL-VIFPVBQESA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 108010085747 Methylmalonyl-CoA Decarboxylase Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- MZGNSEAPZQGJRB-UHFFFAOYSA-N dimethyldithiocarbamic acid Chemical compound CN(C)C(S)=S MZGNSEAPZQGJRB-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- LXJXRIRHZLFYRP-UHFFFAOYSA-N glyceraldehyde 3-phosphate Chemical compound O=CC(O)COP(O)(O)=O LXJXRIRHZLFYRP-UHFFFAOYSA-N 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229960000819 sodium nitrite Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/903—Diazo reactions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/904—Oxidation - reduction indicators
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USUNITEDSTATESOFAMERICA26/07/19910 | |||
| US07/736,583 US5227307A (en) | 1991-07-26 | 1991-07-26 | Test for the rapid evaluation of ischemic state |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE84165B1 IE84165B1 (en) | |
| IE922421A1 true IE922421A1 (en) | 1993-01-27 |
Family
ID=24960447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE242192A IE922421A1 (en) | 1991-07-26 | 1992-07-24 | Test for the rapid evaluation of ischemic states and kit |
| IE20050515A IE20050515A1 (en) | 1991-07-26 | 1992-07-24 | Test for the rapid evaluation of ischemic states and kit |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE20050515A IE20050515A1 (en) | 1991-07-26 | 1992-07-24 | Test for the rapid evaluation of ischemic states and kit |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5227307A (enExample) |
| EP (2) | EP1411356B1 (enExample) |
| JP (1) | JP3194952B2 (enExample) |
| KR (1) | KR100239947B1 (enExample) |
| AT (2) | ATE290688T1 (enExample) |
| AU (2) | AU2318792A (enExample) |
| BR (1) | BR9206312A (enExample) |
| CA (2) | CA2520598A1 (enExample) |
| DE (2) | DE69233487T2 (enExample) |
| DK (1) | DK0596925T3 (enExample) |
| ES (1) | ES2239753T3 (enExample) |
| IE (2) | IE922421A1 (enExample) |
| NO (1) | NO313900B1 (enExample) |
| PT (1) | PT100724B (enExample) |
| WO (1) | WO1993003346A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733524A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5217594A (en) * | 1992-01-15 | 1993-06-08 | Enzyme Technology Research Group, Inc. | Convenient determination of trace lead in whole blood and other fluids |
| US5281700A (en) * | 1992-08-11 | 1994-01-25 | The Regents Of The University Of California | Method of recovering endothelial membrane from tissue and applications thereof |
| DE69533200T2 (de) * | 1994-10-27 | 2005-09-29 | Optigenex, Inc. | Verfahren zur prüfung von immunokompetenz |
| US6248869B1 (en) | 1997-05-29 | 2001-06-19 | Medical Analysis Systems, Inc. | Troponin I forms and use of the same |
| US6136339A (en) * | 1998-08-21 | 2000-10-24 | Gardiner; Paul T. | Food supplements and methods comprising lipoic acid and creatine |
| US6461875B1 (en) * | 1998-10-02 | 2002-10-08 | Ischemia Technologies, Inc. | Test for rapid evaluation of ischemic states and kit |
| US6475743B1 (en) | 1998-10-02 | 2002-11-05 | Ischemia Technologies, Inc. | Marker useful for detection and measurement of free radical damage and method |
| US6492179B1 (en) * | 1998-10-02 | 2002-12-10 | Ischemia Techologies, Inc. | Test for rapid evaluation of ischemic states and kit |
| AU769727B2 (en) * | 1998-10-02 | 2004-02-05 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
| US7297544B2 (en) | 1998-10-02 | 2007-11-20 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
| US7070937B1 (en) * | 1998-10-02 | 2006-07-04 | Ischemia Technologies, Inc. | Marker useful for detection and measurement of free radical damage and method |
| US7449338B2 (en) * | 1998-10-02 | 2008-11-11 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
| WO2000020840A1 (en) * | 1998-10-02 | 2000-04-13 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
| US20050142613A1 (en) * | 1998-10-02 | 2005-06-30 | David Bar-Or | Test for the rapid evaluation of ischemic states and kits |
| US20030130185A1 (en) * | 2000-09-29 | 2003-07-10 | David Bar-Or | Metal-binding compounds and uses therefor |
| US7632803B2 (en) * | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US20030158111A1 (en) * | 1999-10-01 | 2003-08-21 | David Bar-Or | Methods and products for oral care |
| US7592304B2 (en) * | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US20050021235A1 (en) * | 2001-05-30 | 2005-01-27 | Raphael Bar-Or | Method and system for optically performing an assay to determine a medical condition |
| US7262017B2 (en) * | 2001-09-14 | 2007-08-28 | Torrey Pines Institute For Molecular Studies | Diagnostic markers for ischemia |
| JP2005510712A (ja) * | 2001-11-26 | 2005-04-21 | イスケミア・テクノロジーズ・インコーポレーテッド | 虚血の電気化学的検知 |
| CA2500739A1 (en) * | 2002-10-09 | 2004-04-22 | Dmi Biosciences, Inc. | Diagnosis and monitoring of inflammation, ischemia and appendicitis |
| US6884218B2 (en) * | 2002-12-09 | 2005-04-26 | Charles W. Olson | Three dimensional vector cardiograph and method for detecting and monitoring ischemic events |
| WO2004054431A2 (en) * | 2002-12-13 | 2004-07-01 | Ischemia Technologies, Inc. | Tests for the rapid evaluation of ischemic states and kits |
| EP1479779A1 (en) * | 2003-05-19 | 2004-11-24 | Eppendorf Array Technologies SA | Biological signature of manufactured products |
| US7074194B2 (en) * | 2003-05-19 | 2006-07-11 | Ischemia Technologies, Inc. | Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin |
| US7601510B2 (en) * | 2004-03-22 | 2009-10-13 | Ffa Sciences Llc | Development and use of fluorescent probes of unbound analytes |
| WO2006079032A2 (en) * | 2005-01-21 | 2006-07-27 | Ischemia Technologies, Inc. | Targets for detection of ischemia |
| US20060199280A1 (en) * | 2005-03-03 | 2006-09-07 | David Bar-Or | Quantification of proteins |
| US20060257938A1 (en) * | 2005-05-10 | 2006-11-16 | Kleinfeld Alan M | Method of screening for drugs that block ligand binding to a lipid binding protein |
| WO2008060841A2 (en) | 2006-10-27 | 2008-05-22 | Ffa Sciences, Llc | Use of probes for unbound metabolites |
| ES2391666T3 (es) * | 2007-03-29 | 2012-11-28 | L'oréal | Kits y procedimiento para la evaluación del daño en el pelo |
| US8709709B2 (en) | 2007-05-18 | 2014-04-29 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
| CA2684144C (en) | 2007-05-18 | 2018-03-27 | Institute For Molecular Medicine, Inc. | Measurement and uses of oxidative status |
| JP5172467B2 (ja) * | 2008-05-22 | 2013-03-27 | 日本電信電話株式会社 | 血液中成分の定量分光分析法 |
| CN103299181B (zh) | 2011-02-28 | 2015-04-08 | 卢奥克西斯诊断股份有限公司 | 用于测量氧化还原电位的方法及设备 |
| CN102323255B (zh) * | 2011-05-30 | 2013-08-14 | 吉权 | 一种缺血修饰白蛋白测定显色剂及其制备方法 |
| KR101187648B1 (ko) | 2011-08-18 | 2012-10-09 | 한국원자력연구원 | 티올기 검출을 위한 바이오 센서 및 이의 제조방법 |
| KR20150013146A (ko) | 2012-04-19 | 2015-02-04 | 로익스 다이어그노스틱스, 아이엔씨. | 다층겔 |
| SG11201401110WA (en) | 2012-10-23 | 2014-06-27 | Luoxis Diagnostics Inc | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
| US10736551B2 (en) | 2014-08-11 | 2020-08-11 | The Board Of Trustees Of The University Of Illinois | Epidermal photonic systems and methods |
| US11160458B2 (en) | 2014-08-11 | 2021-11-02 | The Board Of Trustees Of The University Of Illinois | Epidermal devices for analysis of temperature and thermal transport characteristics |
| US11064946B2 (en) | 2014-08-11 | 2021-07-20 | The Board Of Trustees Of The University Of Illinois | Devices and related methods for epidermal characterization of biofluids |
| EP3223747B1 (en) | 2014-11-25 | 2020-09-02 | Aytu BioScience, Inc. | Determination of fertility potential from the oxidation-reduction potential of a biological sample |
| WO2017116358A1 (en) | 2015-12-28 | 2017-07-06 | Oran Ismail | Method and apparatus for determination of fatty acid markers using electrical impedance measurement |
| WO2019238554A1 (en) | 2018-06-11 | 2019-12-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting the risk of having lower-extremity artery disease in patients suffering from type 2 diabetes |
| CN109557322A (zh) * | 2018-12-13 | 2019-04-02 | 蓝怡科技集团股份有限公司 | 一种缺血修饰白蛋白校准品及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE795221A (fr) * | 1972-02-12 | 1973-08-09 | Merck Patent Gmbh | Procede et reactif rapide en vue de deceler des stupefiants |
| US4434234A (en) * | 1981-04-02 | 1984-02-28 | The Upjohn Company | Method and kit for silver staining substances supported in matrix |
| US4379848A (en) * | 1981-09-28 | 1983-04-12 | Eastman Kodak Company | Method of analyzing an aqueous liquid for hexacyanoferrates |
| US4468466A (en) * | 1982-02-16 | 1984-08-28 | The United States Of America As Represented By The Department Of Health And Human Services | Silver stains for protein in gels--a modified procedure |
| US4492753A (en) * | 1982-10-06 | 1985-01-08 | Immudx, Inc. | Method and means for assessment and prediction of risk of subsequent ischemic cardiac events |
| US4486282A (en) * | 1983-02-22 | 1984-12-04 | University Patents, Inc. | Precipitation of proteins from salt-containing proteinaceous fluids employing a desalting treatment, and use thereof in selective plasmapheresis |
| US4713327A (en) * | 1985-05-01 | 1987-12-15 | Eastman Kodak Company | Determination of total creatine kinase or an isoenzyme with a multilayer analytical element |
| JPH0625762B2 (ja) * | 1985-06-13 | 1994-04-06 | ヤマサ醤油株式会社 | ミオシン軽鎖の測定法 |
| AU7397487A (en) * | 1986-03-25 | 1987-10-20 | Mclas Technologies, Inc. | Microchemiluminescent assay for detection and quantification of oxidative injury to cells |
| US4786605A (en) * | 1987-06-22 | 1988-11-22 | Eastman Kodak Company | Analytical method and element for protein assay |
-
1991
- 1991-07-26 US US07/736,583 patent/US5227307A/en not_active Expired - Lifetime
-
1992
- 1992-07-10 DE DE69233487T patent/DE69233487T2/de not_active Expired - Fee Related
- 1992-07-10 CA CA002520598A patent/CA2520598A1/en not_active Abandoned
- 1992-07-10 EP EP03027486A patent/EP1411356B1/en not_active Expired - Lifetime
- 1992-07-10 EP EP92915563A patent/EP0596925B1/en not_active Expired - Lifetime
- 1992-07-10 BR BR9206312A patent/BR9206312A/pt not_active IP Right Cessation
- 1992-07-10 DK DK92915563T patent/DK0596925T3/da active
- 1992-07-10 ES ES92915563T patent/ES2239753T3/es not_active Expired - Lifetime
- 1992-07-10 CA CA002113266A patent/CA2113266C/en not_active Expired - Fee Related
- 1992-07-10 AU AU23187/92A patent/AU2318792A/en not_active Abandoned
- 1992-07-10 DE DE69233757T patent/DE69233757D1/de not_active Expired - Fee Related
- 1992-07-10 JP JP50356193A patent/JP3194952B2/ja not_active Expired - Fee Related
- 1992-07-10 AT AT92915563T patent/ATE290688T1/de not_active IP Right Cessation
- 1992-07-10 AT AT03027486T patent/ATE424559T1/de not_active IP Right Cessation
- 1992-07-10 WO PCT/US1992/005668 patent/WO1993003346A1/en not_active Ceased
- 1992-07-24 PT PT100724A patent/PT100724B/pt not_active IP Right Cessation
- 1992-07-24 IE IE242192A patent/IE922421A1/en not_active IP Right Cessation
- 1992-07-24 IE IE20050515A patent/IE20050515A1/en not_active IP Right Cessation
-
1993
- 1993-02-12 US US08/016,971 patent/US5290519A/en not_active Expired - Lifetime
-
1994
- 1994-01-25 NO NO19940256A patent/NO313900B1/no not_active IP Right Cessation
- 1994-01-25 KR KR1019940700225A patent/KR100239947B1/ko not_active Expired - Fee Related
-
1997
- 1997-01-03 AU AU10006/97A patent/AU705300B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1993003346A1 (en) | 1993-02-18 |
| AU2318792A (en) | 1993-03-02 |
| DE69233487T2 (de) | 2006-01-19 |
| EP1411356B1 (en) | 2009-03-04 |
| BR9206312A (pt) | 1995-04-11 |
| NO940256L (no) | 1994-01-25 |
| EP1411356A2 (en) | 2004-04-21 |
| DE69233757D1 (de) | 2009-04-16 |
| CA2113266A1 (en) | 1993-02-18 |
| ATE290688T1 (de) | 2005-03-15 |
| PT100724A (pt) | 1993-09-30 |
| EP0596925A1 (en) | 1994-05-18 |
| ES2239753T3 (es) | 2005-10-01 |
| KR100239947B1 (en) | 2000-01-15 |
| US5227307A (en) | 1993-07-13 |
| ATE424559T1 (de) | 2009-03-15 |
| PT100724B (pt) | 1999-07-30 |
| AU705300B2 (en) | 1999-05-20 |
| US5290519A (en) | 1994-03-01 |
| NO940256D0 (enExample) | 1994-01-25 |
| CA2113266C (en) | 2006-01-10 |
| CA2520598A1 (en) | 1993-02-18 |
| EP0596925A4 (en) | 1996-02-14 |
| AU1000697A (en) | 1997-03-20 |
| JP3194952B2 (ja) | 2001-08-06 |
| EP0596925B1 (en) | 2005-03-09 |
| NO313900B1 (no) | 2002-12-16 |
| IE20050515A1 (en) | 2005-09-21 |
| EP1411356A3 (en) | 2004-05-12 |
| JPH06509645A (ja) | 1994-10-27 |
| DE69233487D1 (de) | 2005-04-14 |
| DK0596925T3 (da) | 2005-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5290519A (en) | Test for the rapid evaluation of ischemic states and kit | |
| IE84165B1 (en) | Test for the rapid evaluation of ischemic states and kit | |
| Burch et al. | Improved method for measurement of delta-aminolevulinic acid dehydratase activity of human erythrocytes | |
| Masato | An improved method for determination of L-ascorbic acid and L-dehydroascorbic acid in blood plasma | |
| Levy et al. | Microdetermination of polyvinylpyrrolidone in aqueous solution and in body fluids | |
| CA2272746C (en) | Measurement of bilirubin albumin binding | |
| Saifer et al. | Photometric microdetermination of amino acids in biological fluids with the ninhydrin reaction | |
| Delvin et al. | Trace elements: functions and assessment of status through laboratory testing | |
| US4393142A (en) | Assay method and reagent for the determination of chloride | |
| Lam et al. | Characterization of carbon disulfide binding in blood and to other biological substances | |
| Rootwelt | Quantitative determination of thiols and disulphides in urine by means of Ellman's reagent and thiolated Sephadex and its application in cystinuria | |
| Bruce et al. | Two-point determination of plasma ammonia with the centrifugal analyzer. | |
| Okamura | A specific method for determination of total ascorbic acids in urine by the α, α-dipyridyl method | |
| JPH04504467A (ja) | アルブミン―テトラゾリウム相互作用を使用するアッセイ | |
| Steinmetz et al. | Modified aca method for determination of iron chelated by deferoxamine and other chelators. | |
| JP3164165B2 (ja) | カルシウムの定量方法 | |
| Wu et al. | Conversion of a qualitative screening test to a quantitative measurement of urinary cystine and homocystine | |
| Keijzer et al. | Rapid and reliable measurement of highly elevated blood ammonia concentrations in children | |
| Bontchev et al. | A rapid and sensitive catalytic method for determination of iron in blood serum | |
| Frazier et al. | An automated fluorometric method for analysis of glycine in biological fluids | |
| Zhao et al. | A novel enzymatic method for determination of homocysteine using electrochemical hydrogen sulfide sensor | |
| Clarkson et al. | A Simple and Rapid Procedure for the Determination of α Amino-nitrogen and Ammonia in Urine | |
| Gibson et al. | Simple metabolic screening tests | |
| Udall et al. | Au Saleh | |
| Tomokuni | Comparison of the Activity Values of Erythrocyte δ-AMINOLEVULINIC Acid Dehydratase, as Measured by Two Different Methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |